98%
921
2 minutes
20
Long non-coding RNA MALAT1 regulates epithelial-mesenchymal transition (EMT) and metastasis in epithelial ovarian cancer (EOC) through a competing endogenous RNA (ceRNA) mechanism involving miRNA modulation. This study aimed to elucidate the molecular pathway by which MALAT1 influences EMT and metastatic behavior via interaction with miR-200c-3p and SNAI2. MALAT1 expression was genetically manipulated in the EOC cell line SK-OV-3 by either overexpression or knockdown. Functional effects on EMT-related protein levels, cell migration, and invasion were assessed using Western blotting, wound healing, and Transwell assays, respectively. Bioinformatics analysis identified miR-200c-3p as a common target of MALAT1 and SNAI2. The MALAT1/miR-200c-3p/SNAI2 axis was further validated by dual-luciferase reporter assays and immunofluorescence staining to confirm direct molecular interactions. Overexpression of MALAT1 enhanced SK-OV-3 cell migration by 20% and invasion by 5%, accompanied by a significant increase in SNAI2 expression (P < 0.01). Conversely, MALAT1 knockdown suppressed these phenotypes. Dual-luciferase assays confirmed that miR-200c-3p directly binds to both MALAT1 and SNAI2 (P < 0.001). miR-200c-3p overexpression reduced MALAT1-driven EMT by downregulating SNAI2 (P < 0.05), whereas restoring SNAI2 reversed the inhibitory effects of MALAT1 silencing on metastasis. This protocol demonstrates that MALAT1 promotes EMT and metastasis in EOC by functioning as a ceRNA that sequesters miR-200c-3p, leading to derepression of SNAI2. The findings provide a novel mechanistic insight and identify the MALAT1/miR-200c-3p/SNAI2 axis as a potential therapeutic target to inhibit ovarian cancer metastasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3791/68653 | DOI Listing |
Nat Commun
September 2025
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90033, California, USA.
Am J Hum Genet
September 2025
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK. Electronic address:
Multiplex assays of variant effect (MAVEs) provide promising new sources of functional evidence, potentially empowering improved classification of germline genomic variants, particularly rare missense variants, which are commonly assigned as variants of uncertain significance (VUSs). However, paradoxically, quantification of clinically applicable evidence strengths for MAVEs requires construction of "truthsets" comprising missense variants already robustly classified as pathogenic and benign. In this study, we demonstrate how benign truthset size is the primary driver of applicable functional evidence toward pathogenicity (PS3).
View Article and Find Full Text PDFCell Rep Med
September 2025
Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway. Electronic address:
Accurate identification of tumor-specific markers is vital for developing chimeric antigen receptor (CAR)-based therapies. While cell surface antigens are seldom cancer-restricted, their post-translational modifications (PTMs), particularly aberrant carbohydrate structures, offer attractive alternatives. Among these, the sialyl-Tn (STn) antigen stands out for its prevalent presence in various epithelial tumors.
View Article and Find Full Text PDFJ Int Med Res
September 2025
Obstetrics and Gynecology Department, Wuhan University Zhongnan Hospital, China.
ObjectiveThis study aimed to evaluate the efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) in patients with advanced ovarian cancer.MethodsA total of 200 patients with advanced ovarian cancer were enrolled in this retrospective study and randomly allocated to two groups (research registry number: 11353). On the first day after abdominal closure, routine treatment was performed in the non-HIPEC group, whereas HIPEC was performed in the HIPEC group.
View Article and Find Full Text PDFBiomed Pharmacother
September 2025
Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Laboratory of Pharmacogenomics, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address:
Patients with epithelial ovarian cancer (EOC) face high mortality due to late diagnosis, recurrence, metastasis, and drug resistance. The NOTCH signaling pathway plays a critical role in cancer progression. This study analyzed NOTCH pathway deregulation in EOC patients and its response to taxane treatment in vitro and in vivo.
View Article and Find Full Text PDF